Research Article
In vitro evaluation of the antimicrobial activities of selected lozenges
Article first published online: 21 SEP 2006
DOI: 10.1002/jps.2600821207
Copyright © 1993 Wiley-Liss, Inc., A Wiley Company
Total views since August 2010: 39
Additional Information
How to Cite
Richards, R. M. E. and Xing, D. K. L. (1993), In vitro evaluation of the antimicrobial activities of selected lozenges. J. Pharm. Sci., 82: 1218–1220. doi: 10.1002/jps.2600821207
Publication History
- Issue published online: 21 SEP 2006
- Article first published online: 21 SEP 2006
- Manuscript Accepted: 8 MAR 1993
- Manuscript Received: 8 SEP 1992
Abstract
The in vitro antimicrobial activities of 10 lozenges (Merothol, Merocets, Merocaine, Strepsils (two varieties), Dequacaine, Dequacets, Zensyls, Tyrozets, and Labosept) were determined by use of a microtiter counting method with Streptococcus pyogenes, Staphylococcus aureus, and Candida albicans as the test organisms. Merothol, Merocets, Merocaine, and both Strepsils formulations all reduced the counts of both S. aureus and S. pyogenes suspensions by ∼6 log cycles within 5 and 20 min, respectively. Merothol, Merocets, and Merocaine also caused a reduction in the counts of the C. albicans suspension ∼5 log cycles within 40 min, but no other lozenge formulation showed rapid and marked activity against C. albicans. Dequacaine and Dequacets showed marked but much slower activities against this yeast. Zensyls caused an ∼6-log-cycle reduction in bacterial counts within 40 min, and Dequacaine, Dequacets, and Tyrozets showed marked but slower antibacterial activities. This work confirmed by a statistically sound in vitro method the in vivo antibacterial activities reported for Merothol, Merocets, and Merocaine, demonstrated equivalent antibacterial activities for Strepsils, and indicated that Merothol, Merocets, and Merocaine also showed marked activities against C. albicans.

1520-6017/asset/JPS_left.gif?v=1&s=becd26fac43b87042ad04af68bbe20d6a12e64fc)
1520-6017/asset/olbannerright.jpg?v=1&s=254f44b422de0f476861bd1056a1789033e2171c)
1520-6017/asset/cover.gif?v=1&s=e589ccf35fd012c675e943835781318cb8666bed)